SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharma reports Phase 1 results supporting biosimilarity criteria for GBR 310

26 Jul 2018 Evaluate

Glenmark Pharmaceuticals has reported results from a Phase 1 study that suggest similarity in pharmacokinetic, pharmacodynamic, safety and immunogenicity profiles between Glenmark’s GBR 310 proposed biosimilar and reference product omalizumab, marketed in the US under the brand name Xolair.

GBR 310 is a recombinant DNA-derived humanized immunoglobulin G1 kappa monoclonal antibody. The proposed indications for GBR 310 are for the treatment of allergic asthma and chronic idiopathic urticaria (CIU).

According to IQVIA sales data for the 12-month period ending May 2018, annual sales of Xolair were approximately $2 billion in the US.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2376.35 2.60 (0.11%)
07-May-2026 10:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1830.30
Dr. Reddys Lab 1306.00
Cipla 1378.25
Zydus Lifesciences 939.85
Lupin 2482.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×